Drug Profile
Research programme: therapeutics - AstraZeneca/MRC Technology
Latest Information Update: 28 Aug 2018
Price :
$50
*
At a glance
- Originator AstraZeneca; MRC Technology
- Developer LifeArc
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Cardiovascular disorders; CNS disorders; Infections; Inflammation; Neurological disorders
Most Recent Events
- 28 Aug 2018 No recent reports of development identified for research development in Inflammation in United Kingdom
- 15 Jun 2017 MRC Technology is now called as LifeArc
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in United Kingdom